Journal of Clinical Oncology, Vol 14, 610-618, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

DJ Boote, IF Dennis, PR Twentyman, RJ Osborne, C Laburte, S Hensel, JF Smyth, MH Brampton and NM Bleehen
Medical Research Council Unit, Medical Research Council Centre, Cambridge, United Kingdom.

PURPOSE: To determine the maximum-tolerated dose (MTD) and toxicity of PSC 833 infusion administered with etoposide for 5 days in patients with cancer, and to determine the effect of PSC 833 on etoposide pharmacokinetics. PATIENTS AND METHODS: Thirty-five patients were entered onto the study, one of whom was ineligible. Etoposide was delivered from day 1 as a 2-hour infusion over 5 consecutive days at a dose of 75 to 100 mg/m2/d. PSC 833 was administered from day 2 as a 2- hour loading dose and as a 5-day continuous infusion. Doses were escalated from 1 to 2 mg/kg (loading dose) and 1 to 15 mg/kg/d (continuous infusion). RESULTS: Thirty-four patients were treated with 53 cycles of PSC 833 and etoposide. Steady-state blood PSC 833 levels more than 1,000 ng/mL were achieved in all patients treated at PSC 833 doses > or = 6.6 mg/kg/d by continuous infusion. Myelosuppression was the most common toxicity. The major dose-related toxicity of PSC 833 was reversible hyperbilirubinemia, which occurred in 83% of cycles. The dose-limiting toxicity of PSC 833 was severe ataxia, which occurred in two of nine patients treated at 12 mg/kg/d and in both of the single patients treated at 13.5 and 15 mg/kg/d. PSC 833 concentrations more than 2,000 ng/mL resulted in an increase in etoposide area under the curve (AUC) of 89%, a decrease in etoposide clearance (Cl) of 45%, a decrease in volume of steady-state distribution (Vss) of 41%, and an insignificant increase in alpha half-life (t 1/2 alpha) and significant increase of beta half-life (t 1/2 beta) of 19% and 77%, respectively. CONCLUSION: PSC 833 can be administered in combination with etoposide with acceptable toxicity. The recommended continuous infusion dose of PSC 833 for this schedule is 10 mg/kg/d over 5 days. PSC 833 results in an increase in etoposide exposure and etoposide doses should be reduced in patients receiving PSC 833.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Lagas, M. L. Vlaming, O. van Tellingen, E. Wagenaar, R. S. Jansen, H. Rosing, J. H. Beijnen, and A. H. Schinkel Multidrug resistance protein 2 is an important determinant of Paclitaxel pharmacokinetics. Clin. Cancer Res., October 15, 2006; 12(20): 6125 - 6132. [Abstract] [Full Text] [PDF]

				R. Advani, B. L. Lum, G. A. Fisher, J. Halsey, D. L. Chin, C. D. Jacobs, and B. I. Sikic A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Ann. Onc., December 1, 2005; 16(12): 1968 - 1973. [Abstract] [Full Text] [PDF]

				V. Dieras, J. Bonneterre, V. Laurence, M. Degardin, J.-Y. Pierga, M.-E. Bonneterre, S. Marreaud, D. Lacombe, and P. Fumoleau Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies Clin. Cancer Res., September 1, 2005; 11(17): 6256 - 6260. [Abstract] [Full Text] [PDF]

				P. M. Fracasso, L. J. Goldstein, D. P. de Alwis, J. S. Rader, M. A. Arquette, S. A. Goodner, L. P. Wright, C. L. Fears, R. J. Gazak, V. A. M. Andre, et al. Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies Clin. Cancer Res., November 1, 2004; 10(21): 7220 - 7228. [Abstract] [Full Text] [PDF]

				S. E. Bates, S. Bakke, M. Kang, R. W. Robey, S. Zhai, P. Thambi, C. C. Chen, S. Patil, T. Smith, S. M. Steinberg, et al. A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2004; 10(14): 4724 - 4733. [Abstract] [Full Text] [PDF]

				P. L. Greenberg, S. J. Lee, R. Advani, M. S. Tallman, B. I. Sikic, L. Letendre, K. Dugan, B. Lum, D. L. Chin, G. Dewald, et al. Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995) J. Clin. Oncol., March 15, 2004; 22(6): 1078 - 1086. [Abstract] [Full Text] [PDF]

				H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis J. Clin. Oncol., November 15, 2003; 21(22): 4239 - 4247. [Abstract] [Full Text] [PDF]

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				E. H. Rubin, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, Y. Lin, R. Musanti, S. L. Grospe, S. L. Smith, D. L. Toppmeyer, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies Clin. Cancer Res., December 1, 2002; 8(12): 3710 - 3717. [Abstract] [Full Text] [PDF]

				C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]

				M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood, July 30, 2002; 100(4): 1224 - 1232. [Abstract] [Full Text] [PDF]

				M. Baekelandt, G. Lehne, C. G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson, and G. B. Kristensen Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer J. Clin. Oncol., June 15, 2001; 19(12): 2983 - 2993. [Abstract] [Full Text] [PDF]

				R. A. Peck, J. Hewett, M. W. Harding, Y.-M. Wang, P. R. Chaturvedi, A. Bhatnagar, H. Ziessman, F. Atkins, and M. J. Hawkins Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin J. Clin. Oncol., June 15, 2001; 19(12): 3130 - 3141. [Abstract] [Full Text] [PDF]

				R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]

				R. Dorr, C. Karanes, C. Spier, T. Grogan, J. Greer, J. Moore, B. Weinberger, G. Schiller, T. Pearce, M. Litchman, et al. Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia J. Clin. Oncol., March 15, 2001; 19(6): 1589 - 1599. [Abstract] [Full Text] [PDF]

				I. Chico, M. H. Kang, R. Bergan, J. Abraham, S. Bakke, B. Meadows, A. Rutt, R. Robey, P. Choyke, M. Merino, et al. Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833 J. Clin. Oncol., February 1, 2001; 19(3): 832 - 842. [Abstract] [Full Text] [PDF]

				A. Patnaik, E. Warner, M. Michael, M. J. Egorin, M. J. Moore, L. L. Siu, P. M. Fracasso, S. Rivkin, I. Kerr, M. Litchman, et al. Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors J. Clin. Oncol., November 1, 2000; 18(21): 3677 - 3689. [Abstract] [Full Text] [PDF]

				E. F. Choo, B. Leake, C. Wandel, H. Imamura, A. J. J. Wood, G. R. Wilkinson, and R. B. Kim Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes Drug Metab. Dispos., June 1, 2000; 28(6): 655 - 660. [Abstract] [Full Text]

				P. M. Fracasso, P. Westerveldt, C. A. Fears, D. M. Rosen, E. G. Zuhowski, L. A. Cazenave, M. Litchman, and M. J. Egorin Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies J. Clin. Oncol., March 1, 2000; 18(5): 1124 - 1124. [Abstract] [Full Text] [PDF]

				S. E. Bates Drug Resistance: Still on the Learning Curve Clin. Cancer Res., November 1, 1999; 5(11): 3346 - 3348. [Full Text] [PDF]

				R. Krishna, N. McIntosh, K. W. Riggs, and L. D. Mayer Doxorubicin Encapsulated in Sterically Stabilized Liposomes Exhibits Renal and Biliary Clearance Properties That Are Independent of Valspodar (PSC 833) under Conditions That Significantly Inhibit Nonencapsulated Drug Excretion Clin. Cancer Res., October 1, 1999; 5(10): 2939 - 2947. [Abstract] [Full Text] [PDF]

				E. J. Lee, S. L. George, M. Caligiuri, T. P. Szatrowski, B. L. Powell, S. Lemke, R. K. Dodge, R. Smith, M. Baer, and C. A. Schiffer Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420 J. Clin. Oncol., September 1, 1999; 17(9): 2831 - 2831. [Abstract] [Full Text] [PDF]

				C. Wandel, R. B. Kim, S. Kajiji, F. P. Guengerich, G. R. Wilkinson, and A. J. J. Wood P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies Cancer Res., August 1, 1999; 59(16): 3944 - 3948. [Abstract] [Full Text] [PDF]

				S. Song, H. Suzuki, R. Kawai, and Y. Sugiyama Effect of PSC 833, a P-Glycoprotein Modulator, on the Disposition of Vincristine and Digoxin in Rats Drug Metab. Dispos., June 1, 1999; 27(6): 689 - 694. [Abstract] [Full Text]

				R. Advani, H. I. Saba, M. S. Tallman, J. M. Rowe, P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis, et al. Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) Blood, February 1, 1999; 93(3): 787 - 795. [Abstract] [Full Text] [PDF]

				R. Robey, S. Bakke, W. Stein, B. Meadows, T. Litman, S. Patil, T. Smith, T. Fojo, and S. Bates Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein-Mediated Drug Efflux by PSC 833 Blood, January 1, 1999; 93(1): 306 - 314. [Abstract] [Full Text] [PDF]

				S. Song, H. Suzuki, T. Terasaki, M. Lemaire, and Y. Sugiyama Modulation of the Tumor Disposition of Vinca Alkaloids by PSC 833 In Vitro and In Vivo J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 963 - 968. [Abstract] [Full Text]

				S. Song, H. Suzuki, R. Kawai, C. Tanaka, I. Akasaka, and Y. Sugiyama Dose-Dependent Effects of PSC 833 on Its Tissue Distribution and on the Biliary Excretion of Endogenous Substrates in Rats Drug Metab. Dispos., November 1, 1998; 26(11): 1128 - 1133. [Abstract] [Full Text]

				V. Fischer, A. Rodríguez-Gascón, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A. E. M. Vickers The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A. Implications for Drug-Drug Interactions and Pharmacological Activity of the Main Metabolite Drug Metab. Dispos., August 1, 1998; 26(8): 802 - 811. [Abstract] [Full Text]

				J. K. Horton, K. N. Thimmaiah, G. A. Altenberg, A. F. Castro, G. S. Germain, G. K. Gowda, and P. J. Houghton Characterization of a Novel Bisacridone and Comparison with PSC 833 as a Potent and Poorly Reversible Modulator of P-Glycoprotein Mol. Pharmacol., December 1, 1997; 52(6): 948 - 957. [Abstract] [Full Text]

				H. Kusuhara, H. Suzuki, T. Terasaki, A. Kakee, M. Lemaire, and Y. Sugiyama P-Glycoprotein Mediates the Efflux of Quinidine across the Blood-Brain Barrier J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 574 - 580. [Abstract] [Full Text]